Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e
AssigneeSelecta Biosciences, Inc.
InventorsPetr Ilyinskii, Yun Gao, Grayson B. Lipford
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus M2 protein.
Claims33
A dosage form comprising synthetic nanocarriers coupled to peptides that are obtained or derived from an ectodomain region of human influenza A virus M2 protein.
(canceled)
5-6. (canceled)
(canceled)
(canceled)
13-15. (canceled)
A dosage form comprising peptides that are obtained or derived from an ectodomain region of human influenza A virus M2 protein, wherein the dosage form generates in a subject polyclonal antibodies that compete for binding to human influenza A virus M2 protein with a control antibody, wherein the control antibody is 14C2.
(canceled)
21-22. (canceled)
29-31. (canceled)
34-37. (canceled)
A method comprising:
- providing synthetic nanocarriers;
- and
- coupling peptides that are obtained or derived from an ectodomain region of human influenza A virus M2 protein to the synthetic nanocarriers.
A process for producing a composition, dosage form or vaccine comprising the steps of:
- providing synthetic nanocarriers;
- and
- coupling peptides that are obtained or derived from an ectodomain region of human influenza A virus M2 protein to the synthetic nanocarriers.
42-47. (canceled)
Dependencies are inferred from the claim text.